CTRI/2010/091/000082
Completed
Phase 1
A Phase I clinical trial to assess safety of the Influenza Vaccine (whole virion, Inactivated) A/H1N1 (Pandemic) in Adults
Serum Institute of India Limited SII0 sites50 target enrollmentTBD
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Serum Institute of India Limited SII
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inclusion Criteria:
- •1\) Normal healthy subjects of 18\-49 years age at the time of screening. 2\)Free of obvious health problems.
Exclusion Criteria
- •1\.Have a known allergy to eggs or other components of the vaccine. 2\.Pregnancy 3\. Participating in other clinical trial during the present trial period 4\. Acute febrile illness or acute infectious disease 5\.History of a previous severe allergic reaction. 6\. History of H1N1 Influenza infection or any influenza vaccination. 7\. Positive serology for HIV antibody, HCV antibody or Hepatitis B surface antigen. 8\.History of Guillain\-Barré Syndrome. 9\. Known history of a bleeding disorder
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Clinical trial for identifying the safety of the Ivermectin bath method.JPRN-UMIN000008994aboratory of medical safety management, Tokyo University of Science6
Active, not recruiting
Phase 1
Study with stem cells from allogenic adipose tissue, in patients with coronavirus severe pneumoniaEUCTR2020-001364-29-ESRed Andaluza de Diseño y Traslación de Terapias Avanzadas-Fundación Progreso y Salud26
Completed
Phase 1
A Phase I clinical trial to evaluate the safety and pharmacokinetics of SHR0302 base ointment at single dose and multiple dose in healthy adult subjectsAtopic dermatitisSkin - Dermatological conditionsACTRN12619001443189Reistone Biopharma Co., Ltd.32
Completed
Phase 1
Salmonella vaccine study in OxfordISRCTN51750695niversity of Oxford31
Active, not recruiting
Phase 1
A dendritic cell vaccine to suppress the immune response to citrullinated antigen in rheumatoid arthritisACTRN12610000373077niquest18